Dec. 11, 2019: Eli Lilly and Company today announced the opening of the LIBRETTO-431 clinical trial for selpercatinib, also known as LOXO-292, for treatment-naïve RET fusion-positive non-small cell lung cancer (NSCLC) patients.
Trial participants will be randomized in order to receive either selpercatinib or platinum-based (carboplatin or cisplatin) and pemetrexed therapy with or without pembrolizumab as initial treatment of their advanced or metastatic RET fusion-positive NSCLC.
“This is an significant milestone in order to further demonstrate the benefit of selpercatinib and also the potential for people living with advanced or metastatic RET fusion-positive non-small cell lung cancer in the first-line setting against the current standard of care”.
Selpercatinib (LOXO-292), is a highly selective and potent, oral investigational new medicine in the clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. https://investor.lilly.com/news-releases/news-release-details/lilly-opens-first-ever-randomized-phase-3-clinical-trial
